All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

ViewsDownloads

Mucinous Breast Carcinoma: Anatomo-Clinical Radiological and Therapeutic Features

DOI: 10.4236/oalib.1104858, PP. 1-9

Subject Areas: Oncology

Keywords: Mucinous Carcinoma, Pure, Mixed, Mammography, Ultrasound, MRI, Histological Grade

Full-Text   Cite this paper   Add to My Lib

Abstract

Introduction: Mucinous carcinoma of the breast constitutes 1% to 4% of all breast cancers. Two different forms of presentation are distinguished: pure mucinous carcinoma and mixed mucinous carcinoma. The purpose of our work was to clarify the anatomo-clinical and radiological particularities of this rare form of breast cancer. Materials and methods: This was a retrospective study of a series of 14 cases of mucinous carcinoma of the breast, including 8 pure mucinous carcinomas and 6 mixed mucinous carcinomas treated at the Maternity and Neonatal Center of Monastir between January 2009 and December 2017. Results: The frequency of mucinous carcinoma of the breast in our study period was 1.9%. The average of the patients was 55 years old. The average tumor size was 40 mm. Mucinous carcinoma of the breast was pure in 8 cases, mixed in 6 cases. The clinical size of pure CM was smaller than that of mixed CM (41 mm vs 45 mm) [p = 0.12]. Axillary adenopathies were found in 28.5% of patients. Mammography detected a total of 19 masses with three cases of multifocality. The average size was 27 mm, there was no significant difference between subtype sizes. Pure CMs had an oval shape in 83% of the cases with microlobulated contours in half of the cases, mixed CM rather had an irregular shape (71%) with indistinct contours (85%) (p = 0.01/p = 0.04). On ultrasound, pure CMs had a homogeneous hypoechogenic oval mass appearance with microlobulated contours enhancing ultrasound. The mixed CMs had an irregular shape of non-geometric contours and heterogeneous hypoechogenic appearance with posterior ultrasound attenuation (p = 0.06). Microcalcifications were present in 37% of pure CM and 60% of mixed CM (p = 0.13). Ganglionic invasion was noted in 28% of cases. The extension assessment was negative in all cases. The tumors were of low histological grade with predominance of SBR I and II grades. They expressed hormone receptors in 85% of cases. Overexpression of the HER2 gene was noted in only one case. Conclusion: It is important to distinguish between the two pure and mixed forms, because the therapeutic attitude and the prognosis depend on it. The pure form remains a favorable prognosis, whereas that of the mixed form matches that of infiltrating ductal carcinomas.

Cite this paper

Korbi, A. , Mhabrech, H. , Farouk, E. , Cherif, O. , Daldoul, A. , Hafsa, C. , Hajji, A. and Faleh, R. (2018). Mucinous Breast Carcinoma: Anatomo-Clinical Radiological and Therapeutic Features. Open Access Library Journal, 5, e4858. doi: http://dx.doi.org/10.4236/oalib.1104858.

References

[1]  Komaki, K., Sakamoto, G., Sugano, H., Morimoto, T. and Monden, Y. (1988) Mucinous Carcinoma of the Breast in Japan. A Prognosis Analysis Based on Morphologic Features. Cancer, 61, 989-996.
https://doi.org/10.1002/1097-0142(19880301)61:5<
989::AID-CNCR2820610522>3.0.CO;2-E
[2]  Thao, V., Yan, X., Funda, M.-B. and Nadeem, M. (2007) Long-Term Outcomes in Patients with Mucinous, Medllary, Tubular, and Invasive Ductual Carcinomas after Lumpectomy. American Journal of Surgery, 194, 527-531.
https://doi.org/10.1016/j.amjsurg.2007.06.012
[3]  Hartman, W.H., Ozzello, L., Sobin, L.H., et al. (1981) Histological Typing of Breast Tumors. 2nd Edition, World Health Organization, Geneva, 19-20.
[4]  Fentiman, I.S., Millis, R.R., Smith, P., et al. (1997) Mucoid Breast Carcinomas: Histology and Prognosis. British Journal Of Cancer, 75, 1061-1065.
https://doi.org/10.1038/bjc.1997.180
[5]  Geschickter, C.F. (1938) Gelatinous Mammary Cancer. Annals of Surgery, 108, 321-346.
https://doi.org/10.1097/00000658-193809000-00001
[6]  Fink, C., Lüdemann, H., Wasser, K. and Delorme, S. (2002) Incidental Finding of a Mucinous Carcinoma of the Breast by Dynamic MRI in a Patient with a History of Breast Trauma. Clinical Imaging, 26, 254-257.
https://doi.org/10.1016/S0899-7071(02)00429-1
[7]  Liu, H., Tan, H., Cheng, Y., Zhang, X., Gu, Y. and Peng, W. (2011) Imaging Findings in Mucinous Breast Carcinoma and Correlating Factors. European Journal of Radiology, 80, 706-712.
[8]  Anan, K., Mitsuyama, S., Tamae, K., et al. (2001) Pathological Features of Mucinous Carcinoma of the Breast Are Favourable for Breast Conserving Therapy. European Journal of Surgical Oncology, 27, 459-463.
https://doi.org/10.1053/ejso.2001.1142
[9]  Kuhl, C.K. (2000) MRI of Breast Tumors. European Radiology, 10, 46-58.
https://doi.org/10.1007/s003300050006
[10]  Komenaka, I.K., El-Tamer, M.B., Troxel, A., Hamele-Bena, D., Joseph, L.A., et al. (2004) Pure Mucinous Carcinoma of the Breast. American Journal of Surgery, 187, 528-532.
https://doi.org/10.1016/j.amjsurg.2003.12.039
[11]  Chtourou, I., Krichen Makni, S., Bahri, I., et al. (2009) Carcinome colloide pur du sein: étude anatmoclinique de sept cas. Cancer Radiothérapie, 13, 37-41.
https://doi.org/10.1016/j.canrad.2008.06.004
[12]  Memis, A., Ozdemir, N., Parildar, M., et al. (2000) Mucinous Colloid Breast Cancer: Mammographic and US Features with Histologic Correlation. European Journal of Radiology, 35, 39-43.
https://doi.org/10.1016/S0720-048X(99)00124-2
[13]  Gilles, R. (2003) L’IRM mammaire. Techniques et valeur actuelle. Cancer Radiothérapie, 7, 115-119.
[14]  Narissada, H., Aoki, T., Sasaguri, T., et al. (2006) Crrelation between Numeric Gadolinium-Enhanced Dynamic MRI Ratios and Prognostic Factors and Histologic Type of Breast Carcinoma. American Journal of Roentgenology, 187, 297-306.
https://doi.org/10.2214/AJR.05.0696
[15]  Diab, S.G., Gary, M.C., Kent Osborne, C., et al. (1999) Tumor Characteristics and Clinical Outcome of Tubular and Mucinous Breast Carcinomas. Journal of Clinical Oncology, 17, 1442-1452.
https://doi.org/10.1200/JCO.1999.17.5.1442
[16]  Kuwabara, M. (1991) MRI of Breast Tumors with Emphasis on Histopathologic Correlation. Nippon Acta Radiologica, 51, 1366-1374.
[17]  Okafuji, T., Yabuuchi, H. and Hiroyasu, S. (2006) MR Imaging Features of Pure Mucinous Carcinoma of the Breast. European Journal of Radiology, 60, 405-413.
https://doi.org/10.1016/j.ejrad.2006.08.006
[18]  Kawashima, M., Tamakiy, Nonaka, T., et al. (2002) MR Imaging of Mucinous Carcinoma of the Breast. AJR, 179, 179-183.
https://doi.org/10.2214/ajr.179.1.1790179
[19]  Lam, W.W., Chu, W.C., Tse, G.M., Ma, T.K. and Tang, A.P. (2006) Role of Fine Needle Aspiration and Trucut Biopsy in Diagnosis of Mucinous Carcinoma of Breast from a Radiologist’s Perspective. Clinical Imaging, 30, 6-10.
[20]  Chen, E.A., Carlson, G.A., Coughlin, B.F., et al. (2000) Routine Chest Roentgenography in Unnecessary in the Work-Up for Stage I and II Breast Cancer. Journal of Clinical Oncology, 18, 3503-3506.
https://doi.org/10.1200/JCO.2000.18.20.3503
[21]  Ciatto, S., Pacini, P., Azzini, V., et al. (1998) Preoperative Staging of Primary Breast Cancer. A Multicentric Study. Cancer, 61, 1038-1040.
https://doi.org/10.1002/1097-0142(19880301)61:5
<1038::AID-CNCR2820610530>3.0.CO;2-Z
[22]  Myers, R.E., Johnston, M., Pritchard, K., Levine, M. and Oliver, T. (2001) Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Baseline Staging Tests in Primary Breast Cancer: A Practice Guideline. Canadian Medical Association Journal, 164, 1439-1444.
[23]  Cox, M., Gilliand, R., OldingSmee, G.W., et al. (1992) An Evaluation of Radionuclide Scanning and Liver Ultrasonography for Staging Breast Cancer. Australian and New Zealand Journal of Surgery, 32, 550-555.
https://doi.org/10.1111/j.1445-2197.1992.tb07049.x
[24]  Park, S., Koo, J., Kim, J.-H., et al. (2010) Clinicopathological Characteristics of Mucinous Carcinoma of the Breast in Korea: Comparison with Invasive Ductual Carcinoma-Not Otherwise Specified. Journal of Korean Medical Science, 25, 361-368. https://doi.org/10.3346/jkms.2010.25.3.361
[25]  Barkley, C.R., Ligibel, J.A., Wong, J.S., et al. (2008) Mucinous Breast Carcinoma: A Large Contempory Series. The American Journal of Surgery, 196, 549-551.
https://doi.org/10.1016/j.amjsurg.2008.06.013
[26]  Fisher, B. and Anderson, S. (1994) Conservative Surgery for the Management of Invasive and Noninvasive Carcinoma of Breast: NSABP Trials. National Surgical Adjuvant Breast and Bowel Project. World Journal of Surgery, 18, 63-69.
https://doi.org/10.1007/BF00348193
[27]  Weber, B., Demange, L., Rigaud, C. and Fernandez-Valoni, A. (1998) Que resteil des indications de mastectomie totale pour cancer? Bulletin du Cancer, 85, 755-762.
[28]  Andre, S., Cunha, F., Bernardo, M., et al. (1995) Mucinous Carcinoma of the Breast: A Pathologic Study of 82 Cases. Journal of Surgical Oncology, 58, 162-167.
https://doi.org/10.1002/jso.2930580305
[29]  Chu, J.-S. and Chang, K.-J. (1999) Mucin Expression in Mucinous Carcinoma and Other Invasive Carcinoma of the Breast. Cancer Letters, 142, 121-127.
https://doi.org/10.1016/S0304-3835(99)00161-5
[30]  Ishikawa, T., Hamaguchi, Y., Ichikawa, Y., et al. (2002) Locally Advanced Mucinous Carcinoma of the Breast with Sudden Growth Acceleration: A Case Report. Japanese Journal of Clinical Oncology, 32, 64-67.
https://doi.org/10.1093/jjco/hyf012
[31]  Zell, J.A., Tsang, W.Y., Taylor, T.H., Mehta, R.S. and Anton-Culver, H. (2009) Prognostic Impact of Human Epidermal Growth Factor-Like Receptor 2 and Hormone Receptor Status in Inflammatory Breast Cancer (IBC): Analysis of 2,014 IBC Patient Cases from the California Cancer Registry. Breast Cancer Research, 11, R9. https://doi.org/10.1186/bcr2225
[32]  Ross, J.S., Slodkowska, E.A., Symmans, W.F., Pusztai, L., Ravdin, P.M., et al. (2009) The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. Oncologist, 14, 320-368.
https://doi.org/10.1634/theoncologist.2008-0230
[33]  Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., et al. (1999) Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed after Chemotherapy for Metastatic Disease. Journal of Clinical Oncology, 17, 2639-2648.
https://doi.org/10.1200/JCO.1999.17.9.2639
[34]  Smith, I., Procter, M., Gelber, R.D., Guillaume, S., Feyereislova, A., et al. (2007) 2-Year Follow-Up of Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer: A Randomised Controlled Trial. The Lancet, 369, 29-36.
https://doi.org/10.1016/S0140-6736(07)60028-2
[35]  Kurtz, J., Jacquemier, J., Torhorst, J., et al. (1989) Conservation Therapy for Breast Cancers Other than Infiltrating Ductal Carcinoma. Cancer, 63, 1630-1635.
https://doi.org/10.1002/1097-0142(19890415)63:8
<1630::AID-CNCR2820630833>3.0.CO;2-U
[36]  Clayton, F. (1986) Pure Mucinous Carcinoma of the Breast: Morphologic Features and Prognostic Correlates. Human Pathology, 17, 34-38.
https://doi.org/10.1016/S0046-8177(86)80152-6

Full-Text


comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

微信:OALib Journal